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hypertension (RH) (i.e., conﬁrmed by ambulatory blood pressure [ABP] monitoring).Background In CKD, uncontrolled hypertension is a major risk factor, but no study has properly investigated the role of RH.Methods We prospectively studied 436 hypertensive CKD patients under nephrology care. Four groups were constituted by
combining 24-h ABP with diagnosis of RH (ofﬁce blood pressure 130/80 mm Hg, despite adherence to 3 full-
dose antihypertensive drugs including a diuretic agent or 4 drugs): control (ABP <125/75 mm Hg without RH);
pseudoresistance (ABP <125/75 mm Hg with RH); sustained hypertension (ABP 125/75 mm Hg without RH);
and true resistance (ABP 125/75 mm Hg with RH). Endpoints of survival analysis were renal (end-stage renal
disease or death) and cardiovascular events (fatal and nonfatal cardiovascular event).Results Age was 65 14 years, men 58%, diabetes 36%, cardiovascular disease 30%, median proteinuria 0.24 (interquartile
range 0.09 to 0.83) g/day, estimated glomerular ﬁltration rate 43  20 ml/min/1.73 m2, ofﬁce blood pressure
146  19/82  12 mm Hg, and 24-h ABP 129  17/72  10 mm Hg. True resistant patients were 22.9%, and
pseudoresistant patients were 7.1%, whereas patients with sustained hypertension were 42.9%, and control subjects
were 27.1%. Over 57 months of follow-up, 109 cardiovascular events and 165 renal events occurred. Cardiovascular
risk (hazard ratio [95% conﬁdence interval]) was 1.24 (0.55 to 2.78) in pseudoresistance, 1.11 (0.67 to 1.84) in
sustained hypertension, and 1.98 (1.14 to 3.43) in true resistance, compared with control subjects. Corresponding
hazards for renal events were 1.18 (0.45 to 3.13), 2.14 (1.35 to 3.40), and 2.66 (1.62 to 4.37).Conclusions In CKD, pseudoresistance is not associated with an increased cardio-renal risk, and sustained hypertension predicts
only renal outcome. True resistance is prevalent and identiﬁes patients carrying the highest cardiovascular risk.
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012; revised manuscript received November 26,being debated (4–6). Recent trials and cohort studies have in
fact disclosed a lack of association between more aggressive
treatment or achieved BP and prognosis (7–10). The absence
of a predictive role of ofﬁce BP in treated CKD might relate,
at least in part, to the high prevalence of white coat hyper-
tension (i.e., high ofﬁce BP and normal ambulatory blood
pressure [ABP]) (3,11,12), which might also explain why
ABP better predicts mortality and end-stage renal disease
(ESRD) than ofﬁce BP (13,14).
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More importantly, the common observation that many
patients with essential hypertension remain hypertensive
despite polytherapy has led to an increased interest in the
independent role of resistant hypertension (RH). Resistant
hypertension is estimated to affect 15% to 30% of patients
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be associated with higher cardio-
vascular morbidity and mortality
(15–17); therefore, it has been
deﬁned as a priority area of re-
search by the American Heart
Association (15). Resistant hy-
pertension is diagnosed when of-
ﬁce BP is not at goal in patients
who are adhering to full doses of
at least 3 different antihyperten-
sive drugsdincluding a diuretic
agentdor normal or elevated BP
in the setting of 4 or more anti-
hypertensive agents (15). Diag-
nosis of RH requires the exclusion
of white coat hypertension, which
identiﬁespseudoresistance (15–18).
In the general RH population,
pseudoresistance is frequent and
heralds a lower cardiovascular riskas compared with true RH (19).
To date, RH has not been properly evaluated in CKD
patients. Indeed, CKD is currently recognized as a frequent
cause of RH in the general hypertensive population, but no
study has adequately addressed the burden of RH in the
speciﬁc setting of hypertensive CKD patients. Preliminary
observations suggest that diagnosis of RH increases after the
ﬁrst 6 months of nephrology care, due to intensiﬁcation of
therapy by the nephrologist (20). However, that exploratory
analysis is limited by the retrospective design and inconsis-
tent ABP assessment.
On the basis of the information available in essential
hypertension (15–17), we can hypothesize that CKD patients
would be at higher risk of RH and that RH would be asso-
ciated with poor prognosis. Therefore, we evaluated preva-
lence, correlates, and long-term prognosis (up to 9 years) of
true RH (i.e., conﬁrmed by ambulatory BP monitoring as
recommended by the American Heart Association) (15) in
a large cohort of hypertensive patients with nondialysis CKD
under regular nephrology care.
Methods
This is a multicenter prospective cohort study of consecutive
patients attending 4 outpatient nephrology clinics in Italy
between 2003 and 2005. The participating institutions share
standardized protocols for the management of CKD,
including ABP monitoring in patients with hypertension,
deﬁned as ofﬁce systolic BP 130 mm Hg and/or diastolic
BP80 mmHg or antihypertensive treatment. Patients were
always seen by the same nephrologist in the clinic. Partici-
pating nephrologists are all well-versed and committed to the
recommended goal of ofﬁce BP <130/80 mm Hg (2).
Patients were instructed to restrict dietary salt (<6 g/day).
Antihypertensive agents were titrated to maximal tolerateddose, used in combination when the BP goal was not reached,
and distributed from 8:00 AM to 10:00 PM. At each visit,
compliance with pharmacological therapy was also evaluated;
physicians asked the number of times the patient had not
taken the prescribed medications in the last 2 weeks. The
patient was identiﬁed as poorly compliant and excluded if the
missing rate was 20%.
As previously described (14), hypertensive patients were
included if they had CKD Stages II to V (not receiving
dialysis/transplant), 6 months of follow-up, and 2 visits
in the renal clinic before the initiation of study. Exclusion
criteria included ofﬁce BP <130/80 mm Hg without
antihypertensive therapy, changes in glomerular ﬁltration
rate (GFR) >30% in the previous 3 months, changes in
antihypertensive therapy 2 weeks before baseline visit, atrial
ﬁbrillation, or inadequate ABP reading. Institutional review
boards of the participating centers approved the protocol,
and informed consent was obtained from all patients before
study enrollment.
Medical, laboratory, and medication information were
collected at baseline, including history of previous cardio-
vascular events and left ventricular hypertrophy (LVH)
diagnosed by echocardiography (yes/no). During the phy-
sician visit (8:00 AM to 11:00 AM), ofﬁce BP was measured
by a nephrologist according to standard methods (21).
Ofﬁce BP values were the mean of the 6 values recorded in
the 2 consecutive days in which ABP device was placed and
removed.
Participating centers shared similar ABP protocols:
Spacelabs 90207 monitors (Spacelabs, Snoqualmie, Wash-
ington) were used, cuff-size was chosen on the basis of patient
arm circumference and ﬁxed to the nondominant arm, and
3 BP readings were taken concomitantly with sphygmom-
anometric measurements to ensure a difference <5 mm Hg
between the 2 sets of values. The monitor recorded BP every
15 min between 7:00 AM and 10:00 PM and every 30 min
between 11:00 PM and 7:00 AM. Daytime and nighttime
periods were derived from the diaries recorded by the patients.
The ABP was always obtained on a workday and under
regular antihypertensive treatment. Patients had no access
to the ABP values. Accuracy of 24-h urine collection was
assessed as previously described (10).
Classiﬁcation of patients. For the purpose of this study,
patients were classiﬁed according to 24-h ABP normal
(<125/75 mm Hg) or high (125 mm Hg and/or 75
mm Hg) and absence or presence of RH (ofﬁce BP 130/
80 mm Hg on 3 full-dose drugs including a diuretic
agent or any ofﬁce BP if the patient was taking 4 drugs).
We chose 24-h ABP, because it includes both activity and
resting BPs. Indeed, nocturnal BP is a main prognostic
indicator of the cardiovascular outcome in CKD patients
(13,14). The cutoff of 125/75 mm Hg was selected,
because it is the lower threshold of normality indicated in
large population-based studies (22). Therefore, patients
were included into 4 groups: control (normal ABP without
RH); pseudoresistance (normal ABP with RH); sustained
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(high ABP with RH).
Outcomes. Renal outcome was deﬁned a priori as a
composite endpoint of ESRD or death, whichever occurred
ﬁrst. The endpoint of ESRDwas reached on the day of the ﬁrst
dialysis session. Death certiﬁcates and autopsy reports were
used to establish the underlying cause of death and
to adjudicate cardiovascular deaths on the basis of the Inter-
national Classiﬁcation of Diseases-Ninth Revision-Clinical
Modiﬁcation. Cardiovascular outcomes included a composite
of cardiovascular death or nonfatal cardiovascular event that
required hospital stay (myocardial infarction, congestive heart
failure, stroke, revascularization, peripheral vascular disease,
and nontraumatic amputation), whichever occurred ﬁrst.
Hospital records were obtained to establish diagnosis (23,24).
Patients were followed-up until January 31, 2012, death, or
ESRD and censored on the date of the last clinic visit.
Statistical analysis. Continuous variables are expressed as
mean  SD or as median (interquartile range [IQR])
according to their distribution. Categorical variables were
reported as percentages. Differences in characteristics of
patients among the 4 groups were tested by means of 1-way
analysis of variance or Kruskal-Wallis (according to their
distribution) and chi-square test for continuous and cate-
gorical variables, respectively.
Multivariable logistic regression analysis was used to identify
the predictors of true resistance. The model accounted
for demographic data (age, sex), clinical characteristics (body
mass index [BMI], diabetes, history of cardiovascular disease,
LVH, poor adherence to low sodium diet deﬁned as urinary
sodium excretion >100 mmol/day), and severity of CKD
(GFR, log–24-h proteinuria).
A multivariable Cox proportional hazards model, stratiﬁed
by center, was used to estimate hazard ratio (HR) and corre-
sponding 95% conﬁdence interval (CI). Cox models were
adjusted for the effect of potentially confounding variables
that were identiﬁed a priori, being recognized as determinants
of renal and cardiovascular outcome (age, sex, BMI, diabetes,
history of cardiovascular disease, natural log-transformed 24-
h proteinuria, and GFR). We tested the association of renal
and cardiovascular endpoint in the 4 groups with patients with
normal ABP and without RH as the reference group.
Data were analyzed with SPSS (version 12.0, SPSS, Inc.,
Chicago, Illinois). All statistical tests were 2-tailed, and
p < 0.05 was considered signiﬁcant.Results
Basal characteristics. Of 472 eligible Caucasian patients,
436 were included in the cohort. Reasons for exclusion have
been reported in detail previously (14). Median follow-up in
the renal clinic before the study start was 8.2 (IQR: 6.7 to
21.6) months and similar in the 4 groups (p ¼ 0.985).
One hundred eighteen patients (27.1%) were classiﬁed
as control subjects, 31 (7.1%) were classiﬁed as pseudor-
esistant, 187 (42.9%) were classiﬁed as having sustainedhypertension, and 100 (22.9%) were classiﬁed as true resis-
tant. The vast majority of RH patients (126 of 131, 96%)
had BP 130/80 mm Hg in the ofﬁce. Demographic,
clinical, and treatment information are presented in Tables 1
and 2. Patients exhibited a high-risk proﬁle as evidenced by
advanced age, high BMI, and large prevalence of diabetes,
LVH, and cardiovascular disease (Table 1). These features
were remarkable in true resistant patients, which were also
characterized by more severe renal disease with the lowest
estimated GFR and the highest 24-h proteinuria. Multi-
variable logistic regression analysis showed that signiﬁcant
baseline correlates of true RH were diabetes (odds ratio
[OR]: 2.84, 95% CI: 1.68 to 4.77), LVH (OR: 2.32, 95%
CI: 1.23 to 4.38), higher proteinuria levels (OR: 2.31, 95%
CI: 1.49 to 3.58), and poor adherence to low salt diet (OR:
2.15, 95% CI: 1.06 to 4.38).
The BP pattern resembled the risk proﬁle observed in
demographic and clinical characteristics (Table 2). True
resistant patients had signiﬁcantly higher BP levels and
prevalence of nondipping status. No difference was detected
in therapeutic regimens in the 4 participating centers.
Seventy-four percent of patients received 2 agents, with
inhibitors of renin-angiotensin system being the most
frequent in the vast majority of the cohort (80%). Diuretic
agents were the second most frequent agent, and all RH
patients received at least 1 diuretic agent by deﬁnition.
Furosemide was represented to a greater extent in the true
resistant group in terms of frequency of use and dose,
whereas other diuretic agents (thiazide drugs in most cases)
were predominant in the pseudoresistant group. Adherence
to the prescribed low salt diet was poor, in contrast to
antihypertensive medication; only 21% of patients showed
urinary sodium excretion 100 mEq/day (p ¼ 0.110 for
inter-group comparison). We found 84 of 187 patients with
sustained hypertension treated with 0 to 1 drugs; of this
subgroup, 26 had normal BP in ofﬁce, and 34 were on
a low-sodium diet regimen.
Survival analysis. Patients were prospectively followed for
52 months, on average (median 57 months, IQR: 36 to
68 months). During this period, 165 renal events and 109
fatal and nonfatal cardiovascular events were documented.
Speciﬁcally, 88 patients progressed to ESRD, and 77 died.
We recorded 63 nonfatal cardiovascular events and 61
cardiovascular deaths (15 occurring after a ﬁrst nonfatal
cardiovascular event); in particular, we registered: 67 acute
myocardial infarctions (39 fatal); 25 strokes (15 fatal); 16
peripheral vascular accidents (2 fatal); and 16 acute heart
failures (5 fatal). Figure 1 depicts unadjusted renal and
cardiovascular event-free survival in the 4 groups. Patients
with normal ABP had the best prognosis for either outcome,
independent of their RH status, whereas the highest risk for
cardio-renal events was observed in true resistance.
Cox analysis (Table 3) conﬁrmed the results of unadjusted
analysis. Pseudoresistant patients did not show a different
cardio-renal risk versus control subjects. Patients with high
ABP had a worse prognosis. However, for these patients,










(n ¼ 100) p Value
Age (yrs) 65.9  13.6 68.7  8.8 62.3  15.1 68.2  10.9 0.001
Male 63 (53.4) 16 (51.6) 118 (63.1) 57 (57.0) 0.310
Diabetes 34 (28.8) 14 (45.2) 47 (25.1) 64 (64.0) <0.0001
Active smoking 20 (16.9) 4 (12.9) 50 (26.7) 26 (26.0) 0.101
BMI (kg/m2) 28.7  5.1 31.4  6.2 28.2  4.8 30.2  5.9 0.001
LVH 64 (54.2) 17 (54.8) 111 (59.4) 83 (83.0) <0.0001
Prior CV disease 59 (24.6) 14 (45.2) 46 (24.6) 44 (44.0) 0.001
CHD 15 (12.7) 8 (25.8) 30 (16.0) 25 (25.0)
TIA/stroke 11 (9.3) 4 (12.9) 9 (4.8) 11 (11.0)
PVD 5 (4.2) 1 (3.2) 7 (3.7) 14 (14.0)
Heart failure 2 (1.7) 2 (6.5) 6 (3.2) 6 (6.0)
Renal disease <0.0001
Hypertension 61 (51.7) 15 (48.4) 65 (34.8) 44 (44.0)
DN 15 (12.7) 8 (25.8) 24 (12.8) 39 (39.0)
Glomerulonephritis 9 (7.6) d 17 (9.1) 8 (8.0)
TIN/ADPKD/other 23 (19.5) 3 (9.7) 57 (30.5) 4 (4.0)
Unknown 10 (8.5) 5 (16.1) 24 (12.8) 5 (5.0)
GFR (ml/min/1.73 m2) 46.0  17.1 45.1  13.8 44.8  21.8 35.0  18.1 <0.0001
Calcium (mg/dl)* 9.5  0.6 9.3  0.5 9.5  0.6 9.3  0.6 0.191
Phosphorus (mg/dl)* 3.8  0.8 3.7  0.9 3.9  0.9 4.0  0.9 0.241
Hemoglobin (g/dl) 13.0  1.8 13.2  1.3 13.1  1.9 12.4  1.7 0.004
Cholesterol (mg/dl) 186  39 197  38 191  36 192  39 0.467
Proteinuria (g/day) 0.2 (0.1–0.6) 0.2 (0.1–0.3) 0.2 (0.1–0.8) 0.7 (0.2–2.3) <0.0001
UNaV (mEq/day) 141  49 150  54 153  65 164  68 0.048
Values are mean SD, n (%), or median (interquartile range). Deﬁnition of groups: Control (normal ambulatory blood pressure [ABP] without resistant
hypertension [RH]); Pseudoresistance (normal ABP with RH); Sustained Hypertension (high ABP without RH); True Resistance (high ABP with RH).
*Data are available in 251 patients.
ADPKD ¼ autosomal polycystic kidney disease; BMI ¼ body mass index; CHD ¼ coronary heart disease; CV ¼ cardiovascular; DN ¼ diabetic
nephropathy; GFR ¼ glomerular ﬁltration rate value by the 4-variable Modiﬁcation of Diet in Renal Disease equation; LVH ¼ left ventricular
hypertrophy; TIN ¼ tubulo-interstitial nephritis; UNaV ¼ urinary sodium excretion.
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a better risk deﬁnition. Indeed, high ABP predicted both
endpoints only if RH was present (true resistance); by
contrast, in nonresistant patients, high ABP (sustained
hypertension) predicted renal but not cardiovascular out-
come. This held true also when considering only ESRD as
renal endpoint (HR: 2.59, 95% CI: 1.23 to 5.44; and HR:
3.46, 95% CI: 1.57 to 7.64, in sustained hypertension and
true resistance, respectively), whereas the risk of all-cause
death increased only in true resistance (HR: 2.59, 95% CI:
1.34 to 5.03). Findings were further conﬁrmed with the
same Cox model after exclusion of control subjects and
pseudoresistant patients; indeed, in comparison with sus-
tained hypertension, true resistance predicted cardiovascular
risk (HR: 2.05, 95% CI: 1.23 to 3.43) but not renal risk
(HR: 1.23, 95% CI: 0.83 to 1.82).
No signiﬁcant interaction in predicting either endpoint
was found between ABP 125/75 mm Hg and diagnosis of
RH when included separately in the Cox model (p ¼ 0.303
and p ¼ 0.730, for cardiovascular and renal endpoint,
respectively). Finally, no interaction was found between RH
and proteinuria (p ¼ 0.546 and p ¼ 0.558, for cardiovascular
and renal endpoint, respectively) and between RH and GFR(p ¼ 0.060 and p ¼ 0.336, for cardiovascular and renal
endpoint, respectively).
Discussion
This study provides new and important insights into the
cardiovascular and renal risk assessment in hypertensive
CKD patients. We demonstrate that two-thirds of our
population had either true resistance (23%) or sustained
hypertension without RH (43%), conditions undetectable by
ofﬁce BP alone, and that these conditions have a different
prognostic valuedtrue resistance is better at predicting
cardiovascular endpoint, whereas sustained hypertension is
more useful for predicting renal outcome. Combining these
2 diagnoses better identiﬁes patients carrying the highest risk
for cardiovascular and renal events.
Our analyses also provide important information with
regard to CKD patients with pseudoresistance that are
characterized by concomitant RH and normal ABP. Indeed,
pseudoresistant patients were similar to control subjects, on
the basis of ABP proﬁles, target organ damage (prevalence
of LVH and severity of renal disease), and long-term
prognosis. This ﬁnding is relevant, because pseudoresistant











Ofﬁce systolic BP 139  17 148  14 146  18 154  20
Ofﬁce diastolic BP 79  10 82  8 84  12 82  12
Ofﬁce systolic BP 130 mm Hg 80 (67.8) 28 (90.3) 153 (81.8) 94 (94.0)
Ofﬁce diastolic BP 80 mm Hg 63 (53.4) 20 (64.5) 133 (71.1) 68 (68.0)
Daytime systolic BP 116  9 115  8 138  13 144  16
Daytime diastolic BP 68  7 65  6 81  10 76  10
Nighttime systolic BP 106  9 106  9 127  17 138  19
Nighttime diastolic BP 60  6 57  7 70  9 70  10
Nondippers 75 (63.6) 19 (61.3) 102 (54.5) 74 (74.0)
BP-lowering drugs 1.9  1.0 3.8  0.9 1.8  1.2 4.2  1.1
0 drug 9 d 32 d
1 drug 40 d 48 d
2 drugs 45 d 57 d
3 drugs 22 19 48 37
>3 drugs 2 12 2 63
ACEI and/or ARB 96 (81.4) 31 (100) 127 (67.9) 94 (94.0)
CCB 31 (26.3) 16 (51.6) 69 (36.9) 73 (73.0)
Beta-blocker drugs 33 (28.0) 17 (54.8) 54 (28.9) 48 (48.0)
Other drug classes 9 (7.6) 8 (25.8) 18 (9.6) 45 (45.0)
Furosemide use 20 (16.9) 13 (41.9) 34 (18.2) 72 (72.0)
Furosemide dose (mg/day) 35  57 19  16 40  40 56  55
Other diuretic agents 25 (21.2) 21 (67.7) 22 (11.8) 47 (47.0)
Values are mean  SD or n (%). Deﬁnition of groups: Control (normal ambulatory blood pressure [ABP] without resistant hypertension [RH]);
Pseudoresistance (normal ABP with RH); Sustained Hypertension (high ABP without RH); True Resistance (high ABP with RH). Nondippers: night/day
ratio of systolic ambulatory blood pressure (BP) (mm Hg) 0.9.
ACEI ¼ angiotensin-converting enzyme inhibitors; ARB ¼ angiotensin receptor blockers; CCB ¼ calcium channel blockers.
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data have been observed in the general hypertensive pop-
ulation. In the Spanish ABP registry, in fact, 12% of the
8,295 patients examined had RH; however, as many as 37%
of them were classiﬁed as having pseudoresistance after ABP
monitoring (19). Our results provide ﬁrst-time observation
in CKD patients that pseudoresistance is frequent and does
not increase the cardio-renal risk as reported in non-CKD
cohorts (18). Pseudoresistant CKD patients should be
identiﬁed to provide correct prognostic information and,
more importantly, to avoid aggressive antihypertensive
therapy. Indeed, these patients were characterized by systolic
BP levels during daytime and, especially at nighttime, close
to the threshold limit of hypoperfusion (100 mm Hg)
(Table 2). Under these circumstances, a tighter control of
BP merely on the basis of the detection of elevated BP in the
ofﬁce might expose patients to ischemia-induced worsening
of cardio-renal damage (6,25) and eventually convert their
prognosis from favorable to unfavorable.
A major ﬁnding of our study is the very high cardio-renal
risk of patients with true resistance (Fig. 1), a group that
represented 35% of patients with high 24-h ABP. The
ﬁnding of such an ominous prognosis is novel but certainly
not surprising, on the basis of the well-established rela-
tionship between RH and cardiovascular risk in essential
hypertension (17,18). Furthermore, studies have shown that
presence of mild-to-moderate GFR reduction and/ormicroalbuminuria ampliﬁes the cardiovascular risk correlated
to RH in the general hypertensive population (26,27). The
present study adds novel evidence of the poor cardio-renal
prognosis of RH and extends its prognostic role to the
patients with established CKD and more-advanced renal
damage.
We observed a different predictive value of true resistance
for the 2 endpoints (Table 3). We found that cardiovascular
outcome was exclusively predicted by true resistance.
Conversely, when analyzing renal survival, true resistance
did not offer any additional predictive value, as compared
with the status of sustained hypertension (HR: 2.66 and
2.14, respectively). Additional Cox models built with sus-
tained hypertension included as reference group further
supported the role of true resistance in predicting only
cardiovascular outcome (see Results). Therefore, combining
ABP and diagnosis of RH allows better risk stratiﬁcation.
This ﬁnding is critical in CKD patients, if one considers that
in this setting the prevalence of true resistance (23%) is
higher as compared with essential hypertension (17,18,28).
Of interest, in the setting of RH, the presence of diabetes,
higher proteinuria, and low GFRdwhich are all predictors
of RH statusddo not further increase the cardiovascular
risk. In particular, although proteinuria is now well-
established as an independent risk factor for cardiovascular
events, our results show that cardiovascular risk did not
increase in RH patients with higher levels of proteinuria.
Figure 1 CV and Renal Survival
Cardiovascular (CV) (A) and renal (B) survival by hypertensive status. Control subjects are in green, pseudoresistance in blue, sustained hypertension in orange, and true
resistance are in red. Cardiovascular events occurred in 25 (21.2%), 8 (25.8%), 40 (21.4%), and 36 (36.0%) patients in control, pseudoresistance, sustained hypertension, and
true resistance groups, respectively. Renal events (end-stage renal disease or death) occurred in 25 (21.2%), 5 (16.1%), 78 (41.7%), and 57 (57%) patients in control,
pseudoresistance, sustained hypertension, and true resistance groups, respectively.
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however, one can speculate that the risk associated with RH
is so pronounced that proteinuria or the other factors
examined do not further enhance it. The pathophysiological
mechanisms underlying the different prognostic value of RH
are beyond the scope of this study; however, we can
hypothesize that persistence of hypertension, despite optimal
antihypertensive treatment, speciﬁcally identiﬁes patients
with more severe vascular damage. Diabetes, left ventricular
hypertrophy, higher proteinuria, and high salt intaked
variables we found independently associated with true
resistancedare in fact all associated with endothelial
dysfunction and arterial stiffness (29–32).Table 3 Multivariable Cox Models for CV and Renal Outcomes
CV Outcome Renal Outcome
Age (1-yr) 1.06 (1.04–1.08)* 1.00 (0.99–1.02)
Male 2.32 (1.49–3.61)* 1.46 (1.05–2.05)*
BMI (1-kg/m2) 0.98 (0.94–1.02) 0.99 (0.96–1.02)
Diabetes (yes vs. no) 1.32 (0.87–2.01) 0.89 (0.62–1.26)
History of CV events (yes vs. no) 2.04 (1.37–3.03)* 1.11 (0.78–1.59)
Log-proteinuria 0.99 (0.72–1.36) 1.35 (1.04–1.75)*
GFR (ml/min/1.73 m2) 0.98 (0.97–0.99)* 0.93 (0.92–0.95)*
Groups
Control Reference Reference
Pseudoresistance 1.24 (0.55–2.78) 1.18 (0.45–3.13)
Sustained hypertension 1.11 (0.67–1.84) 2.14 (1.35–3.40)*
True resistance 1.98 (1.14–3.43)* 2.66 (1.62–4.37)*
Values are hazard ratio (95% conﬁdence interval). Deﬁnition of groups: Control (normal ABP without
RH); Pseudoresistance (normal ABP with RH); Sustained Hypertension (high ABP without RH); True
Resistance (high ABP with RH). *Signiﬁcant hazard ratio.
Abbreviations as in Table 1.Interestingly, dietary sodium restriction improves BP
control in patients with normal renal function and RH (33).
This nonpharmacological intervention is pivotal in CKD,
because this condition is characterized by high sodium
sensitivity of BP (34). Our ﬁnding of an inverse correlation
between adherence to low-salt diet and true resistance
supports this hypothesis. This ﬁnding is not affected by the
extensive use of diuretic agents, because their prescription
was, according to protocol, unchanged for at least 2 weeks
before enrollment, thus excluding diuretic inﬂuence of
external sodium balance at that time (35).
Study limitations. Only Caucasian patients were enrolled,
precluding extrapolation to other ethnic groups. Moreover,
our results apply only to CKD patients under regular tertiary
care. By contrast, the prolonged management in the renal
clinic before baseline might attenuate the imprecision on the
prognostic value of risk factors evaluated as single-time data.
Furthermore, we cannot exclude that prevalence estimates of
RH might be modiﬁed by intensifying therapy (20) or
prolonging ABP monitoring (36). Finally, the observational
nature of this study precludes interpretation of the results in
terms of causality.
Conclusions
Our ﬁndings demonstrate that, in hypertensive CKD
patients treated in renal clinic: 1) true RH is common, being
present in approximately one-fourth of the overall cases and
in 35% of patients with sustained hypertension; and 2)
combining the clinical diagnosis of RH with ABP allows
better risk stratiﬁcation: pseudoresistance is not associated
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2467with a signiﬁcant increase of the cardio-renal risk; sustained
hypertension without RH predicts only renal outcome,
whereas the concomitance of RH and high ABP (true
resistance) speciﬁcally identiﬁes patients carrying the highest
cardiovascular risk.
Therefore, we suggest concurrent evaluation of RH status
and ABP in all hypertensive CKD patients followed in
tertiary care centers. Not only should these patients be
identiﬁed and followed for cardiovascular events, but their
BP should be treated aggressively, and they might also
beneﬁt from alternative therapeutic strategies (37). However,
whether aggressive treatment alters cardiovascular outcome
in this subset of patients remains to be veriﬁed.
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